摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1.2.5.6.7.8-Hexahydro-3H-imidazo<1.2-a>1.3-diazepin | 5627-31-6

中文名称
——
中文别名
——
英文名称
1.2.5.6.7.8-Hexahydro-3H-imidazo<1.2-a>1.3-diazepin
英文别名
1,4,9-Triaza-bicyclo<5.3.0>dec-9-en;2,3,5,6,7,8-hexahydro-1H-imidazo[1,2-a][1,3]diazepine;2,3,5,6,7,8-Hexahydro-1H-imidazo[1,2-a][1,3]diazepin;3H-Imidazo[1,2-a]-1,3-diazepine, 1,2,5,6,7,8-hexahydro-;2,3,5,6,7,8-hexahydro-1H-imidazo[1,2-a][1,3]diazepine
1.2.5.6.7.8-Hexahydro-3H-imidazo<1.2-a>1.3-diazepin化学式
CAS
5627-31-6
化学式
C7H13N3
mdl
MFCD19227991
分子量
139.2
InChiKey
HBWDWJSRXYGILY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    222.3±23.0 °C(Predicted)
  • 密度:
    1.28±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.857
  • 拓扑面积:
    27.6
  • 氢给体数:
    1
  • 氢受体数:
    1

SDS

SDS:8c1d4a790e0dbdb1317b0180dda3dc6d
查看

反应信息

  • 作为反应物:
    描述:
    1.2.5.6.7.8-Hexahydro-3H-imidazo<1.2-a>1.3-diazepin硝酸乙酸酐 作用下, 生成 1-nitro-2,3,5,6,7,8-hexahydro-1H-imidazo[1,2-a][1,3]diazepine; nitrate
    参考文献:
    名称:
    PREPARATION AND CHEMISTRY OF Δ8-HEXAHYDRO-1,4,8-PYRIMIDAZOLE, Δ9-1,5,9-TRIAZABICYCLO(4.4.0)DECENE, AND Δ9-1,4,9-TRIAZABICYGLO(5.3.0)DECENE
    摘要:
    Δ8-六氢-1,4,8-嘧啶,Δ9-1,5,9-三氮杂双环(4.4.0)癸烯和Δ9-1,4,9-三氮杂双环(5.3.0)癸烯的制备方法从相应的2-(ω-羟基烷基氨基)-Δ2-1,3-二氮杂环烯经氯化和脱卤反应得到。这些双环化合物的硝基衍生物在回流乙醇中比1-硝基-2,3,5,6-四氢-1-咪唑(1,2-a)咪唑稳定。
    DOI:
    10.1139/v57-190
  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 在 氢氧化钾 作用下, 生成 1.2.5.6.7.8-Hexahydro-3H-imidazo<1.2-a>1.3-diazepin
    参考文献:
    名称:
    PREPARATION AND CHEMISTRY OF Δ8-HEXAHYDRO-1,4,8-PYRIMIDAZOLE, Δ9-1,5,9-TRIAZABICYCLO(4.4.0)DECENE, AND Δ9-1,4,9-TRIAZABICYGLO(5.3.0)DECENE
    摘要:
    Δ8-六氢-1,4,8-嘧啶,Δ9-1,5,9-三氮杂双环(4.4.0)癸烯和Δ9-1,4,9-三氮杂双环(5.3.0)癸烯的制备方法从相应的2-(ω-羟基烷基氨基)-Δ2-1,3-二氮杂环烯经氯化和脱卤反应得到。这些双环化合物的硝基衍生物在回流乙醇中比1-硝基-2,3,5,6-四氢-1-咪唑(1,2-a)咪唑稳定。
    DOI:
    10.1139/v57-190
点击查看最新优质反应信息

文献信息

  • SOME NEW SULPHONAMIDES AND DERIVATIVES OF BICYCLIC GUANIDINES
    作者:M.-E. Kreling、A. F. McKay
    DOI:10.1139/v58-114
    日期:1958.5.1
    The preparations and bacteriostatic activities of some sulphonamide derivatives of the bicyclic guanidines are described. Some l-(2-hydroxy-3-(aryloxy)propyl)-2,3,5,6-tetrahydro-1-imidaz(1,2-a)imidazoles have also been prepared.
    描述了一些双环胍磺酰胺衍生物的制备和抑菌活性。还制备了一些1-(2-羟基-3-(芳氧基)丙基)-2,3,5,6-四氢-1-咪唑(1,2-a)咪唑。
  • Strong reducing agents containing dimolybdenum Mo24+ units and their oxidized cations with Mo25+/6+ cores stabilized by bicyclic guanidinate anions with a seven-membered ring
    作者:F. Albert Cotton、Carlos A. Murillo、Xiaoping Wang、Chad C. Wilkinson
    DOI:10.1039/b608422b
    日期:——
    The syntheses of two analogues of the bicyclic guanidinate ligand hpp (hpp = the anion of the guanidine-type compound 1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2a]pyrimidine) which contain two fused rings are reported. Each compound contains one seven-membered ring while the other is either a five (Htbd) or a six (Htbu) membered ring. In THF/Bu4NPF6, the dimolybdenum compounds Mo2(tbd)4 and Mo2(tbu)4 are easily oxidized and they have signals in the differential pulse voltammograms at −1.059 and −1.009 V (vs. Ag/AgCl), respectively and for the Mo25+/6+ couples and in the same order −0.242 and −0.312 V for the Mo26+/5+ couples. The two compounds produce the corresponding Mo2(bicyclic guanidinate)4Cl compounds immediately upon dissolution in CH2Cl2 and these easily form species with Mo26+ cores. In Mo2(tbd)4Cl there are two crystallographically independent molecules with Mo–Mo distances of 2.1711(7) and 2.1690(7) Å. The distance between metal atoms increases to 2.206(1) Å upon oxidation to Mo2(tbd)4Cl2 which has a triply bonded Mo26+ core. For the diamagnetic compound Mo2(tbu)4 this distance is 2.0677(9) Å and it increases to 2.133(2) Å upon reduction of the bond order from 4 to 3.5 in the paramagnetic compound Mo2(tbu)4Cl.
    报告了两种含有两个稠环的二环胍基配体hpp(hpp = 胍基化合物1,3,4,6,7,8-六氢-2H-嘧啶并[1,2a]嘧啶的阴离子)类似物的合成。每种化合物包含一个七元环,而另一个要么是五元环(Htbd),要么是六元环(Htbu)。在THF/Bu4NPF6中,二钼化合物Mo2(tbd)4和Mo2(tbu)4很容易被氧化,它们在差分脉冲伏安图中的信号分别为-1.059和-1.009 V(相对于Ag/AgCl),对于Mo25+/6+偶合,信号顺序为-0.242和-0.312 V,对于Mo26+/5+偶合,信号顺序为-0.242和-0.312 V。这两种化合物在溶于CH2Cl2后立即产生相应的Mo2(二环胍基)4Cl化合物,这些化合物很容易形成具有Mo26+核心的物种。在Mo2(tbd)4Cl中,有两个晶体学上独立的分子,Mo-Mo距离分别为2.1711(7)和2.
  • Procédé de synthèse d'esters de l'acide mercapto-3 propionique
    申请人:ELF AQUITAINE EXPLORATION PRODUCTION FRANCE
    公开号:EP0844237B1
    公开(公告)日:2000-05-31
  • SEMI-PERMANENT HAIR STRAIGHTENING COMPOSITION AND METHOD
    申请人:Lubrizol Advanced Materials, Inc.
    公开号:EP3065831A1
    公开(公告)日:2016-09-14
  • Semi-Permanent Hair Straightening Composition And Method
    申请人:LUBRIZOL ADVANCED MATERIALS, INC.
    公开号:US20160296449A1
    公开(公告)日:2016-10-13
    A composition and a process for straightening hair are disclosed. The process includes coating keratin fibers with a composition comprising a thermally-activated agent and a guanidine moiety containing adjuvant compound and contacting the coated keratin fibers with a heating device at a temperature of at least 185 C for sufficient time to modify the keratin fibers.
查看更多

同类化合物

脱氧助间型霉素 化合物RK-33 8-叔-丁基1-乙基6,7-二氢-5H-咪唑并[1,5-A][1,4]二氮杂卓-1,8(9H)-二甲酸基酯 8-(叔丁氧羰基)-6,7,8,9-四氢-5H-咪唑并[1,5-A][1,4]二氮杂-1-羧酸 6-羟基-4,5,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-8(1H)-酮 5-(8-羟基-7,8-二氢-4H-咪唑并[5,4-d][1,3]二氮杂卓-3-基)-3-(羟基甲基)环戊-3-烯-1,2-二醇 4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮 3-[(2-羟基乙氧基)甲基]-3,4,7,8-四氢咪唑并[4,5-d][1,3]二氮杂卓-8-醇 1H-咪唑并[1,5-d〕〔1,4]二氮杂(9CI) 1,4,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-5,8-二酮 (9ci)-1H-咪唑并[1,2-a][1,4]二氮杂卓 5-methylthio-11H-imidazo[1,2-c][1,3]benzodiazepine 2-methoxy-1,4,7-trimethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-5,7-diphenyl-4,5,7,8-tetrahydroimidazo<4,5-e><1,3>diazepin-6-one 6-amino-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione [3-(2-Deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8 tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol]-5'-phosphoric Acid-(3-dodecylmercapto-2-decyloxy)-propyl Ester (4S)-4-benzyl-2-(2,5-dihydroxyphenyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one (4S)-4-benzyl-2-(2,5-dimethoxyphenyl)-3,4-dihydro-5H-pyrido[10,20:1,2]imidazo [4,5-d][1,3]diazepin-5-one (4S)-4-methyl-2-(1-naphthyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one 6-amino-1-(2'-deoxy-β-D-erythropentofuranosyl)-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione 6-amino-1-(2'-deoxy-α-D-erythropentofuranosyl)-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione (4S)-4-methyl-2-(4-acetamidophenyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one 5-(4-methyl-1-piperazinyl)-11H-imidazo[1,2-c][1,3]benzodiazepine monomaleate (8R)-3-[(4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol (R)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol 6-(decylamino)-1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7H-imidazo[4,5-e][1,3]diazepine-4,8-dione (13S)-11-(4-methoxyphenyl)-13-methyl-2,8,10,12-tetrazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7,11-pentaen-14-one (8R)-3-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol 8-Ketodeoxycoformycin 2'-chloropentostatin CO-Vidarabine (8R)-3-[(1S,2R,4R)-2-(benzoyloxymethyl)-1-benzoyloxycyclopent-4-yl]-8-[(tert-butyldimethylsilyl)oxy]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepine (8R)-3-Benzyl-6-(tert-butoxycarbonyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine (8R)-3-(2'-Cyanoethyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine 4-propyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4-propyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 4-isobutyl-7-methyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4,7-diethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4-isobutyl-7-methyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 4,6-diamino-6-(ethylimino)-1,6-dihydroimidazo[4,5-e][1,3]diazepine 4,5-dihydro-8H-6-(N-hexadecyl)amino-1-(2'-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,5-dihydro-8H-6-(N-tetradecyl)amino-1-(2'-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,5-dihydro-8H-6-(N-octadecyl)amino-1-(2-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,6-diamino-6-(octadecylimino)-1,6-dihydroimidazo[4,5-e][1,3]diazepine 8-Imino-2,4-dimethyl-7-phenyl-7,8-dihydro-4H-1,2a,4,5,7-pentaaza-cyclopenta[cd]azulene-3,6-dione 1,4-dimethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 11H-imidazo[1,2-c][1,3]benzodiazepine-5(6H)-thione (8R)-3-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol 2-(4-Chloro-benzylcarbamoyl)-6-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-hexanoic acid benzyl ester (13S)-13-(1H-indol-3-ylmethyl)-2,8,10,12-tetrazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7-tetraene-11,14-dione